Alistair Campbell

Stock Analyst at RBC Capital

(n/a)

# 4,353

Out of 4,667 analysts

2

Total ratings

n/a

Success rate

-33.97%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - General

Stocks Rated by Alistair Campbell

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	GMAB Genmab	Upgrades: Outperform	n/a	$20.45	-	1	Jul 15, 2024
	NVO Novo Nordisk	Downgrades: Sell	n/a	$105.27	-	1	Jan 25, 2022

Genmab

Jul 15, 2024

Upgrades: Outperform

Price Target: n/a

Current: $20.45

Upside: -

Novo Nordisk

Jan 25, 2022

Downgrades: Sell

Price Target: n/a

Current: $105.27

Upside: -